Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
Saved in:
| Title: | Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279. |
|---|---|
| Authors: | Conn E; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Hour S; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Allegakoen D; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Graham G; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Petro J; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Kouassi-Brou M; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Hong SH; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Selvanathan S; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Çelik H; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Toretsky J; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA., Üren A; Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA. |
| Source: | Molecular medicine reports [Mol Med Rep] 2020 Mar; Vol. 21 (3), pp. 1667-1675. Date of Electronic Publication: 2020 Jan 16. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
